FORTRESS BIOTECH INC (FBIO) Stock Price, Forecast & Analysis
NASDAQ:FBIO • US34960Q3074
FBIO Key Statistics, Chart & Performance
The current stock price of FBIO is 3.36 USD. In the past month the price decreased by -3.45%. In the past year, price increased by 107.41%.
FBIO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FBIO. When comparing the yearly performance of all stocks, FBIO is one of the better performing stocks in the market, outperforming 94.24% of all stocks.
FBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FBIO. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
FBIO Financial Highlights
Over the last trailing twelve months FBIO reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 57.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.94% | ||
| ROE | -9.55% | ||
| Debt/Equity | 0.86 |
FBIO Forecast & Estimates
8 analysts have analysed FBIO and the average price target is 10.97 USD. This implies a price increase of 226.34% is expected in the next year compared to the current price of 3.36.
For the next year, analysts expect an EPS growth of 109.83% and a revenue growth 24.62% for FBIO
FBIO Ownership
FBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FBIO
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
FORTRESS BIOTECH INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10014 US
CEO: Lindsay A. Rosenwald
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC / FBIO FAQ
What does FBIO do?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Can you provide the latest stock price for FORTRESS BIOTECH INC?
The current stock price of FBIO is 3.36 USD. The price decreased by -3.45% in the last trading session.
What is the dividend status of FORTRESS BIOTECH INC?
FBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of FBIO stock?
FBIO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in FORTRESS BIOTECH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBIO.
What is the expected growth for FBIO stock?
The Revenue of FORTRESS BIOTECH INC (FBIO) is expected to grow by 24.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for FORTRESS BIOTECH INC?
FORTRESS BIOTECH INC (FBIO) has a market capitalization of 104.29M USD. This makes FBIO a Micro Cap stock.